Advertisements

Pharmaceutical Companies Increase Prices on Over 700 Medications, Including Popular Drugs

by Celia

In recent findings, pharmaceutical companies have raised the prices of more than 700 medications, encompassing well-known drugs such as weight-loss medications Ozempic and Mounjaro, according to research by 46 Brooklyn.

The analysis reveals an average price increase of approximately 4.5% at the beginning of the year, a slightly slower pace compared to the preceding five years when drug prices rose by an average of 5% annually.

Advertisements

Notable among the price hikes are Ozempic and Mounjaro, both belonging to the GLP-1 agonists class designed to aid diabetics in blood sugar regulation. These drugs, recognized for their effectiveness in weight loss, have experienced increased demand, leading to shortages. Novo Nordisk’s Ozempic saw a 3.5% price increase to $984.29 for a month’s supply, while Eli Lilly’s Mounjaro rose by 4.5% to approximately $1,000 for a month’s worth.

Advertisements

Other drugs experiencing price increases this year include:

Advertisements
  • Autoimmune disease medication Enbrel rose by 5%
  • Pain medication Oxycontin rose by 9%
  • Blood thinner Plavix rose by 4.7%
  • Antidepressant Wellbutrin rose by 9.9%

46 Brooklyn’s analysis notes that the majority of brand prescription drug list price increases typically occur in January. Since 2018, over 60% of all brand drug list price increases took place in January.

Advertisements

It’s crucial to note that the analysis, based on wholesale acquisition cost, may differ from what patients ultimately pay. Patient costs are influenced by insurance coverage, rebates, and discounts.

In contrast, some medications experienced significant price reductions at the beginning of the year. Notable decreases include:

  • Insulin products under the Novolog brand name by Novo Nordisk declined by 75%
  • Erectile dysfunction drug Cialis dropped by 19%
  • Antidepressant Prozac declined by 18%
  • Chronic obstructive pulmonary disease medication Advair declined by 22% to 60%, depending on the formulation

While price reductions impact a smaller number of drugs compared to those with increased prices, 46 Brooklyn considers them “truly remarkable from a historical perspective,” particularly given the high-utilization nature of the affected drugs, such as insulins, asthma/COPD inhalers, and central nervous system (CNS) drugs.

You may also like

blank

Dailytechnewsweb is a business portal. The main columns include technology, business, finance, real estate, health, entertainment, etc. 【Contact us: [email protected]

© 2023 Copyright  dailytechnewsweb.com